Meloxicam is Preferable for Long-Term Use
For long-term NSAID therapy, meloxicam is the better choice over diclofenac due to diclofenac's significantly higher cardiovascular mortality risk and worse gastrointestinal tolerability profile.
Cardiovascular Safety: The Critical Differentiator
The most compelling evidence against diclofenac comes from cardiovascular outcomes data. Diclofenac carries substantially higher cardiovascular risks compared to meloxicam, with a 20% increased risk of major adverse cardiovascular events (MACE) and a 57% increased risk of cardiac death 1. This 2022 nationwide Danish study of over 1.6 million patients directly compared diclofenac to meloxicam and found diclofenac's cardiovascular risk profile was comparable to selective COX-2 inhibitors (coxibs), which are known for elevated cardiovascular risks 1.
The American Heart Association guidelines reinforce this concern, showing diclofenac has a relative risk of 1.63 for vascular events compared to placebo in randomized trials, and even worse outcomes in registry data with a mortality RR of 2.40 2. This makes diclofenac one of the most cardiovascular-toxic NSAIDs available.
The cardiovascular risk is particularly pronounced in:
- Women (19% vs 28% increased MACE risk) 1
- Patients with pre-existing cardiovascular disease or risk factors 1
- Higher dose regimens 1
The FDA drug label for diclofenac carries a black box warning specifically highlighting that cardiovascular thrombotic events, MI, and stroke risk "may increase with duration of use" 3—making it particularly problematic for long-term therapy.
Gastrointestinal Tolerability
Meloxicam demonstrates superior GI tolerability compared to diclofenac across multiple large-scale trials. The MELISSA trial, involving 9,323 patients, found significantly fewer GI adverse events with meloxicam (13%) versus diclofenac (19%, p<0.001) 4. Specifically:
- Less dyspepsia (p<0.001)
- Less nausea/vomiting (p<0.05)
- Less abdominal pain (p<0.001)
- Less diarrhea (p<0.001)
- Fewer treatment withdrawals due to GI events (3.02% vs 6.14%, p<0.001) 4
Importantly, there were zero endoscopically-verified ulcer complications with meloxicam versus four with diclofenac, and only 5 patient-days of hospitalization with meloxicam compared to 121 with diclofenac 4.
Efficacy Considerations
While some studies show marginal efficacy advantages for diclofenac, the differences are clinically insignificant and do not justify the substantially higher cardiovascular and GI risks 4. Multiple 6-month trials demonstrated comparable pain relief and functional improvement between meloxicam 7.5 mg and diclofenac 100 mg 5, 6. The MELISSA trial found statistically significant but clinically trivial differences (4.5-9% on VAS scales) that did not meet pre-determined thresholds for clinical significance 4.
Practical Prescribing Algorithm
Start with meloxicam 7.5 mg once daily for long-term therapy. This dose provides:
- Effective anti-inflammatory and analgesic effects
- Once-daily dosing improving compliance 7
- Lower cardiovascular risk profile
- Better GI tolerability
Avoid diclofenac for long-term use in patients with:
- Any cardiovascular disease or risk factors
- History of GI ulceration or bleeding
- Age >65 years
- Concomitant anticoagulant or antiplatelet therapy (including low-dose aspirin)
Critical Caveats
Both drugs carry NSAID class risks including renal toxicity, hypertension, and heart failure 2, 8. However, the magnitude of cardiovascular mortality risk with diclofenac (RR 2.40 for death) makes it unsuitable for long-term therapy in most patients 2.
The FDA specifically notes that diclofenac should be avoided with pemetrexed due to short elimination half-life, while meloxicam requires a 5-day interruption 3—a practical consideration for cancer patients.
Neither drug requires dose adjustment in elderly patients or those with moderate renal/hepatic impairment for short-term use, but long-term safety data remain limited 7. All patients on long-term NSAIDs require monitoring of blood pressure, renal function, and cardiovascular status 8.
The evidence consistently demonstrates that meloxicam's preferential COX-2 selectivity provides a better balance of efficacy and safety for long-term use compared to diclofenac's higher cardiovascular mortality and GI toxicity 4, 1.